Keyphrases
Pembrolizumab
100%
Colorectal Cancer
78%
Metastatic Colorectal Cancer (mCRC)
77%
Chemotherapy
56%
Advanced Solid Tumors
49%
Overall Survival
39%
Previously Treated
34%
Programmed Death-ligand 1 (PD-L1)
33%
Pancreatic Cancer
32%
Monotherapy
31%
Gastric Cancer
28%
Israeli
28%
Objective Response Rate
26%
Antitumor Activity
23%
Treatment-related Adverse Events
23%
Phase II Trial
22%
Neoadjuvant
21%
Colorectal Liver Metastases
21%
Combination Therapy
20%
Oxaliplatin
19%
Clinical Outcomes
18%
Tumor
17%
Resection
17%
Liver
17%
First-in-class
17%
Progression-free Survival
17%
Colorectal Cancer Patients
17%
Pancreatic Neuroendocrine Tumors (pNETs)
16%
Colon Cancer
16%
Adjuvant Chemotherapy
16%
Confidence Interval
16%
Immune Checkpoint Inhibitors
16%
Gastroesophageal Junction Cancer
16%
Primary Tumor
16%
Nonfunctional Pancreatic Neuroendocrine Tumor
16%
Immunoglobulin-like Transcript 4
15%
PD-1 Resistance
15%
Ramucirumab
15%
Selective Internal Radiation Therapy
15%
Specific Antibodies
15%
Resistance Mechanisms
15%
BRCA mutation
15%
Paclitaxel
15%
FOLFIRINOX
15%
Microsatellite Instability-high (MSI-H)
15%
Retrospective Analysis
15%
Pancreatic Ductal Adenocarcinoma
15%
Bevacizumab
14%
Monoclonal Antibody
14%
Neoadjuvant Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Pembrolizumab
88%
Metastatic Colorectal Cancer
62%
Malignant Neoplasm
62%
Solid Malignant Neoplasm
62%
Chemotherapy
60%
Neoplasm
44%
Diseases
42%
Overall Survival
41%
Adverse Event
39%
Colorectal Carcinoma
37%
Pancreas Cancer
33%
Abdominal Cancer
31%
Progression Free Survival
29%
Monotherapy
26%
Adenocarcinoma
24%
Monoclonal Antibody
20%
Combination Therapy
20%
Colon Carcinoma
19%
Antitumor Activity
19%
Recurrent Disease
18%
Fluorouracil
17%
Pharmacokinetics
17%
Ramucirumab
15%
Paclitaxel
15%
Digestive System Cancer
15%
Folinic Acid
14%
Oxaliplatin
14%
Cetuximab
13%
Pancreas Adenocarcinoma
13%
Placebo
12%
Liver Metastasis
11%
Rectum Cancer
11%
Head and Neck Squamous Cell Carcinoma
10%
Pectin
10%
2,5-Dimethoxy-4-iodoamphetamine
10%
Chemoradiation Therapy
10%
Immunoglobulin Antibody
10%
Salicylate Sodium
10%
Prostate Cancer
10%
Chemokine Receptor
10%
Navarixin
10%
Bispecific Antibody
10%
Immunotherapy
10%
Programmed Cell Death
9%
Disease Exacerbation
9%
Programmed Death 1 Ligand 1
9%
Tolerability
8%
Immune Checkpoint Inhibitor
8%
Biological Marker
8%
Bevacizumab
8%
Medicine and Dentistry
Pembrolizumab
59%
Malignant Neoplasm
55%
Overall Survival
53%
Colorectal Carcinoma
50%
Metastatic Colorectal Cancer
42%
Rectum Cancer
41%
Neoplasm
40%
Pancreas Cancer
39%
Progression Free Survival
27%
Diseases
25%
Metastatic Carcinoma
25%
Recurrent Disease
25%
Abdominal Cancer
24%
Pancreas Islet Cell Tumor
24%
Gastroesophageal Junction
24%
Adverse Event
21%
Chemoradiotherapy
19%
Adenocarcinoma
17%
Colon Carcinoma
17%
Neoadjuvant Therapy
16%
Placebo
16%
Primary Tumor
16%
Adjuvant Chemotherapy
16%
4 Iodo 2,5 Dimethoxyamphetamine
15%
BRCA Mutation
15%
Radiation Therapy
15%
Liver Metastasis
13%
Immune Checkpoint Inhibitor
13%
Neoadjuvant Chemotherapy
13%
Cancer
13%
Intention-to-Treat Analysis
13%
Biological Marker
12%
Hepatectomy
12%
Oxaliplatin
12%
Clinical Trial
12%
Immunotherapy
11%
Antineoplastic Activity
11%
Monotherapy
11%
FOLFOX
11%
Family History
11%
Breast Cancer
11%
Hepatocellular Carcinoma
11%
Colorectal Liver Metastasis
10%
Colonoscopy
10%
Solid Malignant Neoplasm
10%
Intraperitoneal Chemotherapy
10%
Ileostomy
10%
Selective Internal Radiation Therapy
10%
Cisplatin
10%
Peritoneum Metastasis
10%
